BofA/Merrill Lynch Downgrades Teva Pharma (TEVA) to Neutral

November 7, 2016 7:11 AM EST
Get Alerts TEVA Hot Sheet
Price: $33.23 -0.72%

Rating Summary:
    18 Buy, 21 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade TEVA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

BofA/Merrill Lynch downgraded Teva Pharma (NYSE: TEVA) from Buy to Neutral with a price target of $48.00.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $40.24 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Downgrades

Related Entities

Merrill Lynch, Bank of America

Add Your Comment